Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Friedrichshall – page 54

851 clinical trials in Bad Friedrichshall, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Friedrichshall at a glance
851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

851 trials in Bad Friedrichshall

Open in trial search

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Dexamfetamine Sulfate for Adults with ADHD

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamfetamine Sulfate
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Breast cancer

Not recruiting

Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Sickle cell anaemia+1

Not recruiting

A Phase 4 Study of Crizanlizumab Treatment for Patients with Sickle Cell Disease Who Previously Participated in Novartis Clinical Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crizanlizumab
  • Sponsor:Novartis Pharma AG

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiovascular disorder+1

Not recruiting

Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lerodalcibep
  • Sponsor:LIB Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab
  • Sponsor:Celgene International II S.a.r.l.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Friedrichshall

What the registry says about research in the country

01 Cardiovascular Disease Research

Clinical trials focusing on atherosclerotic cardiovascular disease are evaluating innovative therapies to reduce major adverse cardiovascular events. These studies aim to improve outcomes for patients at high cardiovascular risk.

  • Coronary Heart Disease
  • Myocardial Infarction
  • Ischemic Stroke Prevention

Research emphasizes the development of new therapeutic approaches for arterial health management.

02 Heart Failure Studies

Groundbreaking research combines empagliflozin with novel compounds to address heart failure management. These trials specifically target patients with reduced left ventricular ejection fraction.

  • Combination Therapy Assessment
  • Cardiovascular Mortality Reduction
  • Hospital Admission Prevention

The studies aim to enhance current treatment protocols for heart failure patients.

03 Cardiac Rhythm Management

Important clinical research in atrial fibrillation and acute coronary syndrome is evaluating new anticoagulation strategies. These trials focus on preventing cardioembolic events and improving post-heart attack outcomes.

  • Stroke Prevention
  • Systemic Embolism Prevention
  • Post-Heart Attack Care

The research aims to establish more effective therapeutic options for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.